224 related articles for article (PubMed ID: 32376001)
1. Comparison of Nafcillin and Cefazolin for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia.
Twilla JD; Algrim A; Adams EH; Samarin M; Cummings C; Finch CK
Am J Med Sci; 2020 Jul; 360(1):35-41. PubMed ID: 32376001
[TBL] [Abstract][Full Text] [Related]
2. Does the Beta-Lactam Matter? Nafcillin versus Cefazolin for Methicillin-Susceptible Staphylococcus aureus Bloodstream Infections.
Burrelli CC; Broadbent EK; Margulis A; Snyder GM; Gold HS; McCoy C; Mahoney MV; Hirsch EB
Chemotherapy; 2018; 63(6):345-351. PubMed ID: 30965335
[TBL] [Abstract][Full Text] [Related]
3. Cefazolin versus Nafcillin for Methicillin-Sensitive Staphylococcus aureus Bloodstream Infection in a California Tertiary Medical Center.
Pollett S; Baxi SM; Rutherford GW; Doernberg SB; Bacchetti P; Chambers HF
Antimicrob Agents Chemother; 2016 Aug; 60(8):4684-9. PubMed ID: 27216053
[TBL] [Abstract][Full Text] [Related]
4. A comparison of safety and outcomes with cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bloodstream infections.
Miller MA; Fish DN; Barber GR; Barron MA; Goolsby TA; Moine P; Mueller SW
J Microbiol Immunol Infect; 2020 Apr; 53(2):321-327. PubMed ID: 30190234
[TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness of nafcillin or cefazolin versus vancomycin in methicillin-susceptible Staphylococcus aureus bacteremia.
Schweizer ML; Furuno JP; Harris AD; Johnson JK; Shardell MD; McGregor JC; Thom KA; Cosgrove SE; Sakoulas G; Perencevich EN
BMC Infect Dis; 2011 Oct; 11():279. PubMed ID: 22011388
[TBL] [Abstract][Full Text] [Related]
6. Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?
Lee S; Choe PG; Song KH; Park SW; Kim HB; Kim NJ; Kim EC; Park WB; Oh MD
Antimicrob Agents Chemother; 2011 Nov; 55(11):5122-6. PubMed ID: 21825299
[TBL] [Abstract][Full Text] [Related]
7. Comparative outcomes of cefazolin versus nafcillin for methicillin-susceptible Staphylococcus aureus bacteraemia: a prospective multicentre cohort study in Korea.
Lee S; Song KH; Jung SI; Park WB; Lee SH; Kim YS; Kwak YG; Kim YK; Kiem SM; Kim HI; Kim ES; Park KH; Kim NJ; Jang HC; Kim HB;
Clin Microbiol Infect; 2018 Feb; 24(2):152-158. PubMed ID: 28694202
[TBL] [Abstract][Full Text] [Related]
8. Comparative Effectiveness of Cefazolin Versus Nafcillin or Oxacillin for Treatment of Methicillin-Susceptible Staphylococcus aureus Infections Complicated by Bacteremia: A Nationwide Cohort Study.
McDanel JS; Roghmann MC; Perencevich EN; Ohl ME; Goto M; Livorsi DJ; Jones M; Albertson JP; Nair R; O'Shea AMJ; Schweizer ML
Clin Infect Dis; 2017 Jul; 65(1):100-106. PubMed ID: 28379314
[TBL] [Abstract][Full Text] [Related]
9. Nafcillin versus cefazolin for the treatment of methicillin-susceptible Staphylococcus aureus bacteremia.
Monogue ML; Ortwine JK; Wei W; Eljaaly K; Bhavan KP
J Infect Public Health; 2018; 11(5):727-731. PubMed ID: 29526442
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the efficacy of nafcillin and glycopeptides as definitive therapy for patients with methicillin-susceptible Staphylococcus aureus bacteremia: a retrospective cohort study.
Oh DH; Kim JJ; Kim J; Seong H; Lee SJ; Kim YC; Kim EJ; Jung IY; Jeong WY; Jeong SJ; Ku NS; Han SH; Choi JY; Song YG; Kim JM
BMC Infect Dis; 2018 Jan; 18(1):60. PubMed ID: 29378565
[TBL] [Abstract][Full Text] [Related]
11. Retrospective Analysis of Adverse Drug Events Between Nafcillin Versus Cefazolin for Treatment of Methicillin-Susceptible
Chan L; Chan-Tompkins NH; Como J; Guarascio AJ
Ann Pharmacother; 2020 Jul; 54(7):662-668. PubMed ID: 31888347
[No Abstract] [Full Text] [Related]
12. β-Lactam Therapy for Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Comparative Review of Cefazolin versus Antistaphylococcal Penicillins.
Li J; Echevarria KL; Traugott KA
Pharmacotherapy; 2017 Mar; 37(3):346-360. PubMed ID: 28035690
[TBL] [Abstract][Full Text] [Related]
13. Clinical implications of cefazolin inoculum effect and β-lactamase type on methicillin-susceptible Staphylococcus aureus bacteremia.
Lee S; Kwon KT; Kim HI; Chang HH; Lee JM; Choe PG; Park WB; Kim NJ; Oh MD; Song DY; Kim SW
Microb Drug Resist; 2014 Dec; 20(6):568-74. PubMed ID: 25000230
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.
Youngster I; Shenoy ES; Hooper DC; Nelson SB
Clin Infect Dis; 2014 Aug; 59(3):369-75. PubMed ID: 24785233
[TBL] [Abstract][Full Text] [Related]
15. Methicillin-Susceptible Staphylococcus Aureus Bacteremia: Cefazolin in Prime But Nafcillin Not Ready for an Exit.
Sarria JC
Am J Med Sci; 2020 Jul; 360(1):3-4. PubMed ID: 32439151
[No Abstract] [Full Text] [Related]
16. Comparison of cefazolin versus oxacillin for treatment of complicated bacteremia caused by methicillin-susceptible Staphylococcus aureus.
Li J; Echevarria KL; Hughes DW; Cadena JA; Bowling JE; Lewis JS
Antimicrob Agents Chemother; 2014 Sep; 58(9):5117-24. PubMed ID: 24936596
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis of trials comparing cefazolin to antistaphylococcal penicillins in the treatment of methicillin-sensitive Staphylococcus aureus bacteraemia.
Rindone JP; Mellen CK
Br J Clin Pharmacol; 2018 Jun; 84(6):1258-1266. PubMed ID: 29600576
[TBL] [Abstract][Full Text] [Related]
18. Tolerability of Cefazolin in Nafcillin-Intolerant Patients for the Treatment of Methicillin-Susceptible Staphylococcus aureus Infections.
Gandhi AM; Shah MD; Donohue LE; Cox HL; Eby JC
Clin Infect Dis; 2021 Nov; 73(9):1650-1655. PubMed ID: 33905485
[TBL] [Abstract][Full Text] [Related]
19. Post-treatment outcomes of ceftriaxone versus antistaphylococcal penicillins or cefazolin for definitive therapy of methicillin-susceptible Staphylococcus aureus bacteremia.
Yetmar ZA; Khodadadi RB; Go JR; Chesdachai S; Abu Saleh OM
Eur J Clin Microbiol Infect Dis; 2023 Apr; 42(4):423-430. PubMed ID: 36800065
[TBL] [Abstract][Full Text] [Related]
20. Implementation of a cefazolin-based stewardship pathway for methicillin-susceptible Staphylococcus aureus bloodstream infections paired with infectious diseases consultation.
Lee BJ; Rao SN; Wang SK; Lee JY; Lakada IY; Gilbert EM; Barr VO; Postelnick MJ; Sutton SH; Zembower TR; Bolon M; Scheetz MH; Rhodes NJ
Int J Antimicrob Agents; 2017 May; 49(5):650-654. PubMed ID: 28279787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]